Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-11-5
pubmed:abstractText
To investigate the clinical effects and security of YiSuiShengXueGranule (YSSXG) on treating 156 patients with beta-thalassemia major. Methods: YSSXG was given orally to 156 patients with beta-thalassemia in GuangXi Autonomous Region (the high incidence area of beta-thalassemia in China) for 3 months as one therapeutic course, 3 times a day, 10 g each time (for children, the dose should be reduced properly according to their body weight and age), and no blood transfusion used during the course. Clinical symptoms and levels of hemoglobin (Hb), red blood cell (RBC), reticulocyte (Ret) and hemoglobin F (HbF) were observed before and after treatment, and side-effects were observed during the course. A 3-6 months follow up study was performed after withdrawal of YSSXG. And systemic gene analysis was conducted with PCR, SSCP-PCR, RT-PCR and DNA sequences analysis and mRNA differently expression technique, in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy, gene expression and its regulation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0918-6158
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2084-7
pubmed:meshHeading
pubmed-meshheading:17978480-Administration, Oral, pubmed-meshheading:17978480-Adolescent, pubmed-meshheading:17978480-Adult, pubmed-meshheading:17978480-Child, pubmed-meshheading:17978480-Child, Preschool, pubmed-meshheading:17978480-Drug Administration Schedule, pubmed-meshheading:17978480-Erythrocytes, pubmed-meshheading:17978480-Female, pubmed-meshheading:17978480-Fetal Hemoglobin, pubmed-meshheading:17978480-Follow-Up Studies, pubmed-meshheading:17978480-Globins, pubmed-meshheading:17978480-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:17978480-Heterozygote, pubmed-meshheading:17978480-Humans, pubmed-meshheading:17978480-Male, pubmed-meshheading:17978480-Medicine, Chinese Traditional, pubmed-meshheading:17978480-Mutation, pubmed-meshheading:17978480-Phytotherapy, pubmed-meshheading:17978480-Polymerase Chain Reaction, pubmed-meshheading:17978480-Polymorphism, Single-Stranded Conformational, pubmed-meshheading:17978480-RNA, Messenger, pubmed-meshheading:17978480-Reticulocytes, pubmed-meshheading:17978480-Retrospective Studies, pubmed-meshheading:17978480-Time Factors, pubmed-meshheading:17978480-Treatment Outcome, pubmed-meshheading:17978480-beta-Thalassemia
pubmed:year
2007
pubmed:articleTitle
Clinical observation on YiSuiShengXueGranule on treating 156 patients with beta-thalassemia major and the molecular mechanism study.
pubmed:affiliation
Department of Molecular-Biology, Guang'AnMen Hospital, China Academy of Traditional Chinese Medicine, Beijing, P.R. China.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't